MAIA Biotechnology Net Income
| MAIA Stock | USD 1.97 0.06 3.14% |
As of the 8th of February, MAIA Biotechnology secures the Downside Deviation of 7.94, mean deviation of 5.88, and Market Risk Adjusted Performance of 5.97. Compared to fundamental indicators, the technical analysis model lets you check possible technical drivers of MAIA Biotechnology, as well as the relationship between them.
MAIA Biotechnology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing MAIA Biotechnology's valuation are provided below:We have found one hundred four available fundamental ratios for MAIA Biotechnology, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of MAIA Biotechnology last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself in the future. As of February 8, 2026, Market Cap is expected to decline to about 38.4 M. In addition to that, Enterprise Value is expected to decline to about 27.8 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -11.3 M | -11.8 M | |
| Net Loss | -20.9 M | -22 M | |
| Net Loss | -20.9 M | -22 M | |
| Net Loss | (1.20) | (1.27) | |
| Net Income Per E B T | 0.89 | 0.77 |
MAIA | Net Income | Build AI portfolio with MAIA Stock |
Analyzing MAIA Biotechnology's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing MAIA Biotechnology's current valuation and future prospects.
Latest MAIA Biotechnology's Net Income Growth Pattern
Below is the plot of the Net Income of MAIA Biotechnology over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in MAIA Biotechnology financial statement analysis. It represents the amount of money remaining after all of MAIA Biotechnology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is MAIA Biotechnology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MAIA Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (23.25 M) | 10 Years Trend |
|
Net Income |
| Timeline |
MAIA Net Income Regression Statistics
| Arithmetic Mean | (10,927,649) | |
| Coefficient Of Variation | (60.24) | |
| Mean Deviation | 5,722,313 | |
| Median | (6,492,782) | |
| Standard Deviation | 6,582,656 | |
| Sample Variance | 43.3T | |
| Range | 16.8M | |
| R-Value | (0.84) | |
| Mean Square Error | 13.5T | |
| R-Squared | 0.71 | |
| Significance | 0.000023 | |
| Slope | (1,096,364) | |
| Total Sum of Squares | 693.3T |
MAIA Net Income History
Other Fundumenentals of MAIA Biotechnology
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
MAIA Biotechnology Net Income component correlations
MAIA Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for MAIA Biotechnology is extremely important. It helps to project a fair market value of MAIA Stock properly, considering its historical fundamentals such as Net Income. Since MAIA Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MAIA Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MAIA Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. Expected growth trajectory for MAIA significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive MAIA Biotechnology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
MAIA Biotechnology's market price often diverges from its book value, the accounting figure shown on MAIA's balance sheet. Smart investors calculate MAIA Biotechnology's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since MAIA Biotechnology's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that MAIA Biotechnology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MAIA Biotechnology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
MAIA Biotechnology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MAIA Biotechnology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MAIA Biotechnology.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in MAIA Biotechnology on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding MAIA Biotechnology or generate 0.0% return on investment in MAIA Biotechnology over 90 days. MAIA Biotechnology is related to or competes with Elutia, Lantern Pharma, Bioatla, PolyPid, RenovoRx, Annovis Bio, and Veru. MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commerciali... More
MAIA Biotechnology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MAIA Biotechnology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MAIA Biotechnology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.94 | |||
| Information Ratio | 0.1294 | |||
| Maximum Drawdown | 45.94 | |||
| Value At Risk | (10.75) | |||
| Potential Upside | 12.6 |
MAIA Biotechnology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for MAIA Biotechnology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MAIA Biotechnology's standard deviation. In reality, there are many statistical measures that can use MAIA Biotechnology historical prices to predict the future MAIA Biotechnology's volatility.| Risk Adjusted Performance | 0.1224 | |||
| Jensen Alpha | 1.08 | |||
| Total Risk Alpha | 0.3198 | |||
| Sortino Ratio | 0.1282 | |||
| Treynor Ratio | 5.96 |
MAIA Biotechnology February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1224 | |||
| Market Risk Adjusted Performance | 5.97 | |||
| Mean Deviation | 5.88 | |||
| Semi Deviation | 7.3 | |||
| Downside Deviation | 7.94 | |||
| Coefficient Of Variation | 710.31 | |||
| Standard Deviation | 7.87 | |||
| Variance | 61.92 | |||
| Information Ratio | 0.1294 | |||
| Jensen Alpha | 1.08 | |||
| Total Risk Alpha | 0.3198 | |||
| Sortino Ratio | 0.1282 | |||
| Treynor Ratio | 5.96 | |||
| Maximum Drawdown | 45.94 | |||
| Value At Risk | (10.75) | |||
| Potential Upside | 12.6 | |||
| Downside Variance | 63.11 | |||
| Semi Variance | 53.32 | |||
| Expected Short fall | (6.20) | |||
| Skewness | 0.1749 | |||
| Kurtosis | 1.36 |
MAIA Biotechnology Backtested Returns
MAIA Biotechnology is very risky given 3 months investment horizon. MAIA Biotechnology has Sharpe Ratio of 0.15, which conveys that the company had a 0.15 % return per unit of volatility over the last 3 months. We were able to collect and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.19% are justified by taking the suggested risk. Use MAIA Biotechnology Market Risk Adjusted Performance of 5.97, mean deviation of 5.88, and Downside Deviation of 7.94 to evaluate company specific risk that cannot be diversified away. MAIA Biotechnology holds a performance score of 11 on a scale of zero to a hundred. The firm secures a Beta (Market Risk) of 0.18, which conveys not very significant fluctuations relative to the market. As returns on the market increase, MAIA Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding MAIA Biotechnology is expected to be smaller as well. Use MAIA Biotechnology standard deviation, treynor ratio, downside variance, as well as the relationship between the total risk alpha and value at risk , to analyze future returns on MAIA Biotechnology.
Auto-correlation | 0.68 |
Good predictability
MAIA Biotechnology has good predictability. Overlapping area represents the amount of predictability between MAIA Biotechnology time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MAIA Biotechnology price movement. The serial correlation of 0.68 indicates that around 68.0% of current MAIA Biotechnology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.68 | |
| Spearman Rank Test | 0.61 | |
| Residual Average | 0.0 | |
| Price Variance | 0.19 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
MAIA Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, MAIA Biotechnology reported net income of (23.25 Million). This is 106.81% lower than that of the Biotechnology sector and 133.2% lower than that of the Health Care industry. The net income for all United States stocks is 104.07% higher than that of the company.
MAIA Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MAIA Biotechnology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MAIA Biotechnology could also be used in its relative valuation, which is a method of valuing MAIA Biotechnology by comparing valuation metrics of similar companies.MAIA Biotechnology is currently under evaluation in net income category among its peers.
MAIA Fundamentals
| Return On Equity | -26.91 | ||||
| Return On Asset | -1.48 | ||||
| Current Valuation | 62.06 M | ||||
| Shares Outstanding | 37.03 M | ||||
| Shares Owned By Insiders | 19.81 % | ||||
| Shares Owned By Institutions | 6.69 % | ||||
| Number Of Shares Shorted | 1.63 M | ||||
| Price To Book | 1,751 X | ||||
| EBITDA | (23.25 M) | ||||
| Net Income | (23.25 M) | ||||
| Cash And Equivalents | 8.15 M | ||||
| Cash Per Share | 0.75 X | ||||
| Total Debt | 6.52 M | ||||
| Current Ratio | 2.78 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (15.7 M) | ||||
| Short Ratio | 3.07 X | ||||
| Earnings Per Share | (0.74) X | ||||
| Target Price | 12.14 | ||||
| Number Of Employees | 13 | ||||
| Beta | -0.045 | ||||
| Market Capitalization | 72.95 M | ||||
| Total Asset | 10.16 M | ||||
| Retained Earnings | (87.23 M) | ||||
| Working Capital | 6.32 M | ||||
| Net Asset | 10.16 M |
About MAIA Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MAIA Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MAIA Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MAIA Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:Check out For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. Expected growth trajectory for MAIA significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive MAIA Biotechnology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
MAIA Biotechnology's market price often diverges from its book value, the accounting figure shown on MAIA's balance sheet. Smart investors calculate MAIA Biotechnology's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since MAIA Biotechnology's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that MAIA Biotechnology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MAIA Biotechnology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.